Patents by Inventor Hye Guk Ryu

Hye Guk Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers
    Patent number: 11939334
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: March 26, 2024
    Assignee: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers
    Patent number: 11912710
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: February 27, 2024
    Assignee: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • PLK1 selective degradation inducing compound
    Patent number: 11833208
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Grant
    Filed: March 27, 2021
    Date of Patent: December 5, 2023
    Assignee: UPPTHERA, INC.
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND
    Publication number: 20230372498
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 23, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • NOVEL PLK1 DEGRADATION INDUCING COMPOUND
    Publication number: 20230242541
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Application
    Filed: August 10, 2022
    Publication date: August 3, 2023
    Applicant: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • NOVEL PLK1 DEGRADATION INDUCING COMPOUND
    Publication number: 20230219966
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Application
    Filed: August 10, 2022
    Publication date: July 13, 2023
    Applicant: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • VANILLIN DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230203006
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: June 29, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230159515
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: May 25, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230158158
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: May 25, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • PLK1 Selective Degradation Inducing Compound
    Publication number: 20230104076
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: April 6, 2023
    Inventors: Si Woo CHOI, Soo Hee RYU, Ji Hoon RYU, San Ha SON, Hwa Jin LEE, Seong Hoon KIM, Boas NAM, Im Suk MIN, Hye Guk RYU, Keum Young KANG
  • HMG-CoA Reductase Degradation Inducing Compound
    Publication number: 20230078961
    Abstract: The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reductase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.
    Type: Application
    Filed: March 30, 2021
    Publication date: March 16, 2023
    Inventors: Si Woo CHOI, Soo Hee RYU, Ji Hoon RYU, San Ha SON, Hwa Jin LEE, Seong Hoon KIM, Eun Bin LEE, Hye Guk RYU, Im Suk MIN, Jun Kyu LEE
  • Atorvastatin derived HMG-CoA reductase degradation inducing compound
    Patent number: 11066391
    Abstract: The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 20, 2021
    Assignee: UPPTHERA
    Inventors: Soo Hee Ryu, Hwa Jin Lee, Seong Hoon Kim, Hye Guk Ryu, Eun Bin Lee